ConductScience.org, home

Paper3916740

Complete androgen blockade for the treatment of prostate cancer.

Labrie F and 2 others. Important Adv Oncol, 1985. Cited by 136 papers, by iCite.

Cite this record

ConductScience Library. Complete androgen blockade for the treatment of prostate cancer. Papers, record 3916740. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3916740

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Complete androgen blockade for the treatment of prostate cancer.
PubMed
Journal
Important Adv Oncol
PubMed
Year
1985
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
136
iCite
Relative citation ratio, by iCite
4.71
iCite
Revised in PubMed
2006-11-15
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Labrie FF
2Dupont AA
3Belanger AA

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdrenalectomyMajor topic
Androgen AntagonistsMajor topic
AndrogensMajor topic
Antineoplastic AgentsMajor topic
EstrogensMajor topic
Gonadotropin-Releasing HormoneMajor topic
Neoplasms, Hormone-DependentMajor topic
OrchiectomyMajor topic
Prostatic NeoplasmsMajor topic
Acid Phosphatase
Bone Neoplasms
Combined Modality Therapy
Drug Evaluation
Humans
Male

Source PubMed

Download CSV of topics

Cited by29

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 136 citations.

PMIDTitleJournalYearIn PapersSource
33780276Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance).J Urol2021https://conductscience.org/library/papers/33780276PubMed
33722247The inhibitory effect of melatonin on human prostate cancer.Cell Commun Signal2021https://conductscience.org/library/papers/33722247PubMed
32016080The importance of antiandrogen in prostate cancer treatment.Ann Transl Med2019https://conductscience.org/library/papers/32016080PubMed
31948021Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?Animals (Basel)2020https://conductscience.org/library/papers/31948021PubMed
31504033Systematically understanding the immunity leading to CRPC progression.PLoS Comput Biol2019https://conductscience.org/library/papers/31504033PubMed
29440921Adult-onset acne: prevalence, impact, and management challenges.Clin Cosmet Investig Dermatol2018https://conductscience.org/library/papers/29440921PubMed
24303091Increased bone mineral density in patients with non-alcoholic steatohepatitis.World J Hepatol2013https://conductscience.org/library/papers/24303091PubMed
21243019Blockade of testicular and adrenal androgens in prostate cancer treatment.Nat Rev Urol2011https://conductscience.org/library/papers/21243019PubMed
17387321Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.Prostate Cancer Prostatic Dis2007https://conductscience.org/library/papers/17387321PubMed
11988089Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate.Biochem J2002https://conductscience.org/library/papers/11988089PubMed
11173616Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment.Pathol Oncol Res1996https://conductscience.org/library/papers/11173616PubMed
10408706Controversies in the management of advanced prostate cancer.Br J Cancer1999https://conductscience.org/library/papers/10408706PubMed
10147438Clinical and economic considerations in the treatment of prostate cancer.Pharmacoeconomics1994https://conductscience.org/library/papers/10147438PubMed
9699133DHEA as physiological replacement therapy at menopause.J Endocrinol Invest1998https://conductscience.org/library/papers/9699133PubMed
9592622Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.Clin Pharmacokinet1998https://conductscience.org/library/papers/9592622PubMed
9241550Cyproterone acetate monotherapy in advanced prostatic carcinoma.Int Urol Nephrol1997https://conductscience.org/library/papers/9241550PubMed
8012037Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat.Breast Cancer Res Treat1994https://conductscience.org/library/papers/8012037PubMed
7647332Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.Breast Cancer Res Treat1995https://conductscience.org/library/papers/7647332PubMed
3926197Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.Br Med J (Clin Res Ed)1985https://conductscience.org/library/papers/3926197PubMed
3718913Ocular toxicity of Anandron in patients treated for prostatic cancer.Br J Ophthalmol1986https://conductscience.org/library/papers/3718913PubMed

See all 29 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3916740

GET https://conductscience.org/api/papers/v1/3916740/cited_by?page=2